Sofosbuvir/daclatasvir

Sofosbuvir/daclatasvir

Sovodak 60/400
Combination of
Daclatasvir NS5A inhibitor
Sofosbuvir NS5B (RNA polymerase) inhibitor
Clinical data
Trade names Darvoni, Sovodak
Pregnancy
category
  • US: B (No risk in non-human studies)
Routes of
administration
Oral
Legal status
Legal status

Daclatasvir/sofosbuvir is a two-drug combination for the treatment of hepatitis C.[1] It is given as a single daily pill containing daclatasvir, the viral NS5A inhibitor and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase.[2]

Society and culture

Daclatasvir/sofosbuvir was developed by a Bangladeshi pharmaceutical company Beacon Pharmaceuticals Limited and approved by Directorate General of Drug Administration, Ministry of Health and Family Welfare, People's Republic of Bangladesh.

The same combination is produced by an Iranian company under the trade name of Sovodak.[3] The combination includes 400 mg sofosbuvir and 60 mg daclatasvir and has been used in clinical trials since 2015.[4] Sovodak was approved by the Iranian Food and Drug Administration on October 2015[5] and is currently marketed in Iran as the treatment of choice for all genotypes of hepatitis C as recommended by the national Iranian guideline for treating hepatitis C.[6]

References



This article is issued from Wikipedia - version of the 11/26/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.